CLINICAL TRIALS PROFILE FOR RUXIENCE
✉ Email this page to a colleague
Biosimilar Clinical Trials for RUXIENCE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04555811 ↗ | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | Recruiting | Masonic Cancer Center, University of Minnesota | Phase 1 | 2020-09-22 | This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for RUXIENCE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04189588 ↗ | Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine | Completed | TerSera Therapeutics | Phase 2 | 2020-03-25 | This study is designed to compare the incidence of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions while on maintenance or retreatment. |
| NCT04189588 ↗ | Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine | Completed | JDP Therapeutics, Inc. | Phase 2 | 2020-03-25 | This study is designed to compare the incidence of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions while on maintenance or retreatment. |
| NCT04189588 ↗ | Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine | Completed | TerSera Therapeutics LLC | Phase 2 | 2020-03-25 | This study is designed to compare the incidence of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions while on maintenance or retreatment. |
| NCT04555811 ↗ | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | Recruiting | Masonic Cancer Center, University of Minnesota | Phase 1 | 2020-09-22 | This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma. |
| NCT04688788 ↗ | Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis | Recruiting | Aalborg University Hospital | Phase 3 | 2021-04-28 | The DanNORMS study is phase 3 non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety. |
| NCT04688788 ↗ | Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis | Recruiting | Aarhus University Hospital | Phase 3 | 2021-04-28 | The DanNORMS study is phase 3 non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety. |
| NCT04688788 ↗ | Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis | Recruiting | Danske Regioner | Phase 3 | 2021-04-28 | The DanNORMS study is phase 3 non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RUXIENCE
Condition Name
| Condition Name for RUXIENCE | |
| Intervention | Trials |
| Chronic Lymphocytic Leukemia | 3 |
| Small Lymphocytic Lymphoma | 2 |
| High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | 1 |
| Primary Progressive Multiple Sclerosis | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for RUXIENCE
Trials by Country
Clinical Trial Progress for RUXIENCE
Clinical Trial Phase
Clinical Trial Sponsors for RUXIENCE
Sponsor Name
